Swertiamarin
CAS: 17388-39-5
Rif. 3D-MS10475
1g | 865,00 € | ||
50mg | 180,00 € | ||
100mg | 260,00 € | ||
250mg | 406,00 € | ||
500mg | 544,00 € |
Informazioni sul prodotto
- (4aR,5R,6S)-5-Ethenyl-6-(β-<span class="text-smallcaps">D</span>-glucopyranosyloxy)-4,4a,5,6-tetrahydro-4a-hydroxy-1H,3H-pyrano[3,4-c]pyran-1-one
- (4aR,5R,6S)-5-ethenyl-4a-hydroxy-1-oxo-4,4a,5,6-tetrahydro-1H,3H-pyrano[3,4-c]pyran-6-yl beta-D-glucopyranoside
- (5R,6S)-5-ethenyl-4a-hydroxy-1-oxo-4,4a,5,6-tetrahydro-1H,3H-pyrano[3,4-c]pyran-6-yl beta-D-glucopyranoside
- 1H,3H-Pyrano(3,4-c)pyran-1-one, 5-ethenyl-6-(beta-D-glucopyranosyloxy)-4,4a,5,6-tetrahydro-4a-hydroxy-, (4aR-(4aalpha,5beta,6alpha))-
- 1H,3H-Pyrano(3,4-c)pyran-1-one, 5-ethenyl-6-(beta-d-glucopyranosyloxy)-4,4a,5,6-tetrahydro-4a-hydroxy-, (4aR,5R,6S)-
- 1H,3H-Pyrano[3,4-c]pyran-1-one, 5-ethenyl-6-(β-<span class="text-smallcaps">D</span>-glucopyranosyloxy)-4,4a,5,6-tetrahydro-4a-hydroxy-, (4aR,5R,6S)-
- 1H,3H-Pyrano[3,4-c]pyran-1-one, 5-ethenyl-6-(β-<span class="text-smallcaps">D</span>-glucopyranosyloxy)-4,4a,5,6-tetrahydro-4a-hydroxy-, [4aR-(4aα,5β,6α)]-
- Brn 0055278
- Swertamarin
- Swertiamarine
- Vedi altri sinonimi
- Swertiamaroside
- Swertimarin
- (4aR,5R,6S)-5-Ethenyl-6-(β-D-glucopyranosyloxy)-4,4a,5,6-tetrahydro-4a-hydroxy-1H,3H-pyrano[3,4-c]pyran-1-one
- 1H,3H-Pyrano[3,4-c]pyran-1-one, 5-ethenyl-6-(β-D-glucopyranosyloxy)-4,4a,5,6-tetrahydro-4a-hydroxy-, [4aR-(4aα,5β,6α)]-
- 1H,3H-Pyrano[3,4-c]pyran-1-one, 5-ethenyl-6-(β-D-glucopyranosyloxy)-4,4a,5,6-tetrahydro-4a-hydroxy-, (4aR,5R,6S)-
Swertiamarin is a natural compound that has been shown to have anti-steatotic activity in animal models. Swertiamarin was found to reduce the activity index for liver steatosis and increase the activity index for hepatic steatosis, which may be due to its ability to inhibit 5-hydroxytryptamine (5-HT)2 receptors. Swertiamarin also inhibits the activation of c-jun N-terminal kinase, which is a protein involved in cellular events such as apoptosis and inflammation. The molecular docking analysis of swertiamarin with the human 5-HT2A receptor showed that swertiamarin binds to the receptor with high affinity, inhibiting its function. The use of swertiamarin in combination with other natural compounds could be used as an alternative treatment for hepatic steatosis in humans.
Proprietà chimiche
Richiesta tecnica su: 3D-MS10475 Swertiamarin
Se si desidera richiedere un preventivo o effettuare un ordine, si prega invece di aggiungere i prodotti desiderati al carrello e poi richiedere un preventivo o un ordine dal carrello. È più veloce, più economico, e potrà beneficiare degli sconti disponibili e di altri vantaggi.